These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 21982065)

  • 1. Improving the clinical risk score: an analysis of molecular biomarkers in the era of modern chemotherapy for resectable hepatic colorectal cancer metastases.
    Maithel SK; Gönen M; Ito H; Dematteo RP; Allen PJ; Fong Y; Blumgart LH; Jarnagin WR; D'Angelica MI
    Surgery; 2012 Feb; 151(2):162-70. PubMed ID: 21982065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
    Kim SH; Kwon HC; Oh SY; Lee DM; Lee S; Lee JH; Roh MS; Kim DC; Park KJ; Choi HJ; Kim HJ
    Am J Clin Oncol; 2009 Feb; 32(1):38-43. PubMed ID: 19194123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Messenger RNA expression of TS and ERCC1 in colorectal cancer and matched liver metastasis.
    Kobayashi H; Sugihara K; Uetake H; Higuchi T; Yasuno M; Enomoto M; Iida S; Azuma M; Mori R; Omori A; Lenz HJ; Danenberg KD; Danenberg PV
    Int J Oncol; 2008 Dec; 33(6):1257-62. PubMed ID: 19020759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prognostic factors for long-term outcome of hepatic resection for colorectal liver metastases].
    Aldrighetti L; Castoldi R; Di Palo S; Arru M; Stella M; Orsenigo E; Gavazzi F; Ferla G; Di Carlo V; Staudacher C
    Chir Ital; 2005; 57(5):555-70. PubMed ID: 16241086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
    Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does neoadjuvant chemotherapy reveal disease precluding surgical treatment of initially resectable colorectal cancer liver metastases?
    Reddy SK; Tsung A; Marsh JW; Geller DA
    J Surg Oncol; 2012 Jan; 105(1):55-9. PubMed ID: 21842519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased thymidylate synthase gene expression in liver metastases from colorectal carcinoma: implications for chemotherapeutic options and survival.
    Bathe OF; Franceschi D; Livingstone AS; Moffat FL; Tian E; Ardalan B
    Cancer J Sci Am; 1999; 5(1):34-40. PubMed ID: 10188059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical value of hepatocyte growth factor and its receptor--c-met for liver cancer patients with hepatectomy.
    Wu F; Wu L; Zheng S; Ding W; Teng L; Wang Z; Ma Z; Zhao W
    Dig Liver Dis; 2006 Jul; 38(7):490-7. PubMed ID: 16627020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longterm results and prognostic indicators after cryotherapy and hepatic arterial chemotherapy with or without resection for colorectal liver metastases in 224 patients: longterm survival can be achieved in patients with multiple bilateral liver metastases.
    Yan TD; Padang R; Morris DL
    J Am Coll Surg; 2006 Jan; 202(1):100-11. PubMed ID: 16377503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prediction of the efficacy of modified FOLFOX6 therapy according to the mRNA levels of thymidylate synthase (TS), excision repair cross-complementing-1 and -2( ERCC-1 and ERCC-2) and methylenetetrahydrofolate dehydrogenase( MTHFD) in the primary lesion of colorectal cancer].
    Ishibashi K; Okada N; Tajima Y; Ishiguro T; Kuwabara K; Ohsawa T; Kumamoto K; Tsuji Y; Haga N; Iwama T; Ishida H; Onouchi T; Yakabi K
    Gan To Kagaku Ryoho; 2011 Nov; 38(12):2220-3. PubMed ID: 22202336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of hepatocyte growth factor on progression of liver metastasis in colorectal cancer.
    Osada S; Matsui S; Komori S; Yamada J; Sanada Y; Ihawa A; Tanaka Y; Tokuyama Y; Okumura N; Nonaka K; Hosono Y; Takahashi T; Yamaguchi K; Yoshida K
    Hepatogastroenterology; 2010; 57(97):76-80. PubMed ID: 20422876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Study on the prognostic value of hepatocyte growth factor and c-met for patients with hepatocellular carcinoma].
    Wu FS; Zheng SS; Wu LJ; Ding W; Ma ZM; Wang ZM; Teng LS; Zhao WH
    Zhonghua Wai Ke Za Zhi; 2006 May; 44(9):603-8. PubMed ID: 16784653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P53 overexpression in colorectal metastases confined to the liver and outcome of liver resection.
    Heisterkamp J; van Bommel J; Hop WC; Tilanus HW; Zondervan PE; IJzermans JN
    Hepatogastroenterology; 1999; 46(30):3109-14. PubMed ID: 10626170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy.
    Righi L; Papotti MG; Ceppi P; Billè A; Bacillo E; Molinaro L; Ruffini E; Scagliotti GV; Selvaggi G
    J Clin Oncol; 2010 Mar; 28(9):1534-9. PubMed ID: 20177021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Results of prophylactic hepatic arterial chemotherapy for liver metastases of Dukes C colorectal cancer--correlation with tumoral expression of dihydropyrimidine dehydrogenase, thymidylate synthase, p53, or orotate phosphoribosyl transferase].
    Ishida H; Yamada H; Shirakawa K; Nakada H; Ohsawa T; Takeuchi I; Okada N; Yokoyama M; Inokuma S; Suzuki T; Odaka A; Hoshino T; Murata N; Hashimoto D; Itoyama S; Mori T; Matsumoto Y; Miura T
    Gan To Kagaku Ryoho; 2003 Oct; 30(11):1621-6. PubMed ID: 14619479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CXCR4 expression predicts patient outcome and recurrence patterns after hepatic resection for colorectal liver metastases.
    Yopp AC; Shia J; Butte JM; Allen PJ; Fong Y; Jarnagin WR; DeMatteo RP; D'Angelica MI
    Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S339-46. PubMed ID: 21584832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin.
    Zucali PA; Giovannetti E; Destro A; Mencoboni M; Ceresoli GL; Gianoncelli L; Lorenzi E; De Vincenzo F; Simonelli M; Perrino M; Bruzzone A; Thunnissen E; Tunesi G; Giordano L; Roncalli M; Peters GJ; Santoro A
    Clin Cancer Res; 2011 Apr; 17(8):2581-90. PubMed ID: 21262916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer.
    Kemeny N; Huang Y; Cohen AM; Shi W; Conti JA; Brennan MF; Bertino JR; Turnbull AD; Sullivan D; Stockman J; Blumgart LH; Fong Y
    N Engl J Med; 1999 Dec; 341(27):2039-48. PubMed ID: 10615075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetic study in rectal cancer patients treated with preoperative chemoradiotherapy: polymorphisms in thymidylate synthase, epidermal growth factor receptor, GSTP1, and DNA repair genes.
    Páez D; Salazar J; Paré L; Pertriz L; Targarona E; del Rio E; Barnadas A; Marcuello E; Baiget M
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1319-27. PubMed ID: 21570215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903.
    Posner MC; Niedzwiecki D; Venook AP; Hollis DR; Kindler HL; Martin EW; Schilsky RL; Goldberg RM; Mayer RJ
    Ann Surg Oncol; 2008 Jan; 15(1):158-64. PubMed ID: 18008108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.